Jaeok Park

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6310142/publications.pdf

Version: 2024-02-01

		623734	713466
23	489	14	21
papers	citations	h-index	g-index

23	23	23	750
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Synthesis and Evaluation of Structurally Diverse C-2-Substituted Thienopyrimidine-Based Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase. Journal of Medicinal Chemistry, 2022, 65, 2471-2496.	6.4	5
2	Structural and functional insights into esterase-mediated macrolide resistance. Nature Communications, 2021, 12, 1732.	12.8	21
3	Structural and phylogenetic analyses of resistance to next-generation aminoglycosides conferred by AAC(2â€²) enzymes. Scientific Reports, 2021, 11, 11614.	3.3	9
4	Revisiting the Catalytic Cycle and Kinetic Mechanism of Aminoglycoside O-Nucleotidyltransferase(2â€³): A Structural and Kinetic Study. ACS Chemical Biology, 2020, 15, 686-694.	3.4	0
5	Assorted dysfunctions of endosomal alkali cation/proton exchanger SLC9A6 variants linked to Christianson syndrome. Journal of Biological Chemistry, 2020, 295, 7075-7095.	3.4	13
6	Phosphonate and Bisphosphonate Inhibitors of Farnesyl Pyrophosphate Synthases: A Structure-Guided Perspective. Frontiers in Chemistry, 2020, 8, 612728.	3.6	19
7	Chirality-Driven Mode of Binding of Î±-Aminophosphonic Acid-Based Allosteric Inhibitors of the Human Farnesyl Pyrophosphate Synthase (hFPPS). Journal of Medicinal Chemistry, 2019, 62, 9691-9702.	6.4	10
8	The Structural Dynamics of Engineered Î²-Lactamases Vary Broadly on Three Timescales yet Sustain Native Function. Scientific Reports, 2019, 9, 6656.	3.3	19
9	Inhibition of farnesyl pyrophosphate (FPP) and/or geranylgeranyl pyrophosphate (GGPP) biosynthesis and its implication in the treatment of cancers. Critical Reviews in Biochemistry and Molecular Biology, 2019, 54, 41-60.	5.2	52
10	A potential gain-of-function variant of SLC9A6 leads to endosomal alkalinization and neuronal atrophy associated with Christianson Syndrome. Neurobiology of Disease, 2019, 121, 187-204.	4.4	21
11	Unraveling the Prenylationâ€“Cancer Paradox in Multiple Myeloma with Novel Geranylgeranyl Pyrophosphate Synthase (GGPPS) Inhibitors. Journal of Medicinal Chemistry, 2018, 61, 6904-6917.	6.4	33
12	Human farnesyl pyrophosphate synthase is allosterically inhibited by its own product. Nature Communications, 2017, 8, 14132.	12.8	32
13	Pharmacophore Mapping of Thienopyrimidine-Based Monophosphonate (ThP-MP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase. Journal of Medicinal Chemistry, 2017, 60, 2119-2134.	6.4	21
14	Crystallographic and thermodynamic characterization of phenylaminopyridine bisphosphonates binding to human farnesyl pyrophosphate synthase. PLoS ONE, 2017, 12, e0186447.	2.5	5
15	Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase. Bioorganic and Medicinal Chemistry Letters, 2015, 25, 1117-1123.	2.2	15
16	Human isoprenoid synthase enzymes as therapeutic targets. Frontiers in Chemistry, 2014, 2, 50.	3.6	37
17	Structure of human farnesyl pyrophosphate synthase in complex with an aminopyridine bisphosphonate and two molecules of inorganic phosphate. Acta Crystallographica Section F, Structural Biology Communications, 2014, 70, 299-304.	0.8	9
18	Maintenance of Native-like Protein Dynamics May Not Be Required for Engineering Functional Proteins. Chemistry and Biology, 2014, 21, 1330-1340.	6.0	29

#	Article	IF	Citations
19	Multistage Screening Reveals Chameleon Ligands of the Human Farnesyl Pyrophosphate Synthase: Implications to Drug Discovery for Neurodegenerative Diseases. Journal of Medicinal Chemistry, 2014, 57, 5764-5776.	6.4	29
20	Crystal structures of hFPPS in complex with novel anticancer drug leads. Acta Crystallographica Section A: Foundations and Advances, 2014, 70, C712-C712.	0.1	0
21	Thienopyrimidine Bisphosphonate (ThPBP) Inhibitors of the Human Farnesyl Pyrophosphate Synthase: Optimization and Characterization of the Mode of Inhibition. Journal of Medicinal Chemistry, 2013, 56, 7939-7950.	6.4	43
22	Ternary complex structures of human farnesyl pyrophosphate synthase bound with a novel inhibitor and secondary ligands provide insights into the molecular details of the enzymeâ€™s active site closure. BMC Structural Biology, 2012, 12, 32.	2.3	21
23	Design and Synthesis of Active Site Inhibitors of the Human Farnesyl Pyrophosphate Synthase: Apoptosis and Inhibition of ERK Phosphorylation in Multiple Myeloma Cells. Journal of Medicinal Chemistry, 2012, 55, 3201-3215.	6.4	46